Market research
DMAC DiaMedica Therapeutics Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 530M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- Not available
- Beta
- 0.91
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA25253X2077
- Market cap
- 530M
- P/E ratio
- Not available
- Analyst target
- 15.5
- Dividend yield
- Not available
- Beta
- 0.91
About
About DiaMedica Therapeutics Inc
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Research context
DiaMedica Therapeutics Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DMAC discussion.
5 years, 6 months ago
DiaMedica Therapeutics Inc is currently in a long term downtrend where the price is trading 45.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
DiaMedica Therapeutics Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 69.4% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 64.0% to $-3M since the same quarter in the previous year.
Based on the above factors, DiaMedica Therapeutics Inc gets an overall score of 1/5.